胃康胶囊联合兰索拉唑肠溶胶囊对胃溃疡患者胃肠激素、炎症反应和T淋巴细胞亚群的影响

摘要 目的：观察胃康胶囊联合兰索拉唑肠溶胶囊治疗胃溃疡的疗效及对胃肠激素、炎症反应和T淋巴细胞亚群的影响。方法：选择2018年9月~2021年5月在中国人民解放军31694部队医院消化内科接受治疗的80例胃溃疡患者作为观察对象，根据信封抽签法分为对照组和观察组，各为40例。对照组患者接受兰索拉唑肠溶胶囊治疗，观察组患者接受胃康胶囊联合兰索拉唑肠溶胶囊治疗，连续治疗6周。对比两组临床疗效、幽门螺杆菌（Hp）根除率和溃疡愈合率，观察治疗期间不良反应发生情况，对比两组治疗前、治疗6周后的胃肠激素、血清炎症因子和T淋巴细胞亚群指标水平的变化。结果：观察组的临床总有效率较对照组高（P<0.05）。观察组的Hp根除率和溃疡愈合率均高于对照组（P<0.05）。治疗6周后，两组CD3⁺、CD4⁺、CD4⁺/CD8⁺较治疗前升高，CD8⁺ 较治疗前下降，且观察组的改善效果优于对照组（P<0.05）。治疗6周后，两组胃动素（MTL）水平较治疗前升高，胃泌素（GAS）水平较治疗前下降，且观察组的改善效果优于对照组（P<0.05）。治疗6周后，两组高迁移率族蛋白B1（HMGB1）、白介素-6（IL-6）、C反应蛋白（CRP）水平较治疗前下降，且观察组的改善效果优于对照组（P<0.05）。两组不良反应发生率对比无统计学差异（P>0.05）。结论：兰索拉唑肠溶胶囊联合胃康胶囊可提高胃溃疡患者的溃疡愈合率和Hp根除率，其作用机制可能与调节胃肠激素、炎症反应和T淋巴细胞亚群指标水平有关。

Effects of Weikang Capsule Combined with Lansoprazole Enteric Coated Capsule on Gastrointestinal Hormones, Inflammatory Response and T Lymphocyte Subsets in Patients with Gastric Ulcer

ABSTRACT Objective: To observe the efficacy of Weikang capsule combined with lansoprazole enteric coated capsule in the treatment of gastric ulcer and its effects on gastrointestinal hormones, inflammatory response and T lymphocyte subsets. Methods: 80 patients with gastric ulcer who were treated in the Department of Gastroenterology,31694 Army Hospital of the Chinese people''s Liberation Army from September 2018 to May 2021 were selected as the observation objects. According to the envelope lottery method, they were divided into control group and observation group, with 40 cases in each group. The patients in the control group were treated with lansoprazole enteric coated capsule, and the patients in the observation group were treated with Weikang capsule combined with lansoprazole enteric coated capsule, continuous treatment for 6 weeks. The clinical efficacy, helicobacter pylori (Hp) eradication rate and ulcer healing rate of the two groups were compared, the occurrence of adverse reactions during treatment was observed, and the changes of gastrointestinal hormones, serum inflammatory factors and T lymphocyte subsets index levels before and 6 weeks after treatment were compared between the two groups. Results: The total clinical effective rate of the observation group was higher than that of the control group (P<0.05). The Hp eradication rate and ulcer healing rate of the observation group were higher than those of the control group(P<0.05). 6 weeks after treatment, CD3⁺, CD4⁺ and CD4⁺/CD8⁺ in both groups were higher than those before treatment, while CD8⁺ was lower than that before treatment, and the improvement effect of observation group was better than that of control group(P<0.05). 6 weeks after treatment, the level of motilin (MTL) in both groups was higher than that before treatment, the level of gastrin (GAS) was lower than that before treatment, and the improvement effect of observation group was better than that of control group(P<0.05). 6 weeks after treatment, the levels of high mobility group protein B1(HMGB1), interleukin-6(IL-6) and C-reactive protein (CRP) in the two groups decreased compared with those before treatment, and the improvement effect of the observation group was better than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Lansoprazole enteric coated capsule combined with Weikang capsule can improve the ulcer healing rate and HP eradication rate in patients with gastric ulcer. Its mechanism may be related to the regulation of gastrointestinal hormones, inflammatory response and T lymphocyte subsets index levels.